Company Profiles

driven by the PitchBook Platform

Amplyx

Description

Developer of broad-spectrum antifungal agents designed to treat invasive fungal infections. The company's small-molecule therapy, APX001, uses both intravenous and oral formulations to address the need for treatment in both the hospital setting and continued convenient treatment after discharge from hospital, enabling patients undergoing chemotherapy and other immunosuppressive treatments, with compromised immune systems, to get proper treatment for life-threatening invasive fungal infections due to candida, aspergillus and rare molds.

2006

Founded

PRIVATE

Status

11-50

Employees

Series B

Latest Deal Type

$49.2M

Latest Deal Amount

$53.7M

Total Amount Raised

Description

Developer of broad-spectrum antifungal agents designed to treat invasive fungal infections. The company's small-molecule therapy, APX001, uses both intravenous and oral formulations to address the need for treatment in both the hospital setting and continued convenient treatment after discharge from hospital, enabling patients undergoing chemotherapy and other immunosuppressive treatments, with compromised immune systems, to get proper treatment for life-threatening invasive fungal infections due to candida, aspergillus and rare molds.

Website:

www.amplyx.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Other Pharmaceuticals and Biotechnology

Primary Office

12730 High Bluff Drive Suite 160 San Diego, CA 92130United States +1 (858) 345-1755
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Amplyx's full profile, request a free trial.

Amplyx Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Amplyx Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Amplyx Investors (15)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
3x5 Special Opportunity PartnersVenture CapitalMinority000 0000000 0000
Ariel Southeast Angel PartnersAngel GroupMinority000 0000000 0000
BiobritVenture CapitalMinority000 0000000 0000
BioMed VenturesCorporate Venture CapitalMinority000 0000000 0000
Golden SeedsVenture CapitalMinority000 0000000 0000
3x5 Special Opportunity Partners Venture Capital
Ariel Southeast Angel Partners Angel Group
Biobrit Venture Capital
BioMed Ventures Corporate Venture Capital
Golden Seeds Venture Capital

Amplyx Executive Team (7)

NameTitleBoard
Seat
Contact
Info
Ciara Kennedy Ph.DPresident, Chief Executive Officer and Board Member
Karen Shaw Ph.DChief Scientific Officer
Susan DubéVice President of Business Development and Administration
Pamela WedelVice President of Clinical Operations
Elizabeth Gordon Ph.DVice President, Regulatory Affairs
Ciara Kennedy Ph.D President, Chief Executive Officer and Board Member
Karen Shaw Ph.D Chief Scientific Officer
Susan Dubé Vice President of Business Development and Administration
Pamela Wedel Vice President of Clinical Operations
Elizabeth Gordon Ph.D Vice President, Regulatory Affairs

Amplyx Board Members (5)

NameRepresentingRoleSinceContact
Info
Edward MathersNew Enterprise AssociatesPartner000 0000
Elaine Heron Ph.DAmplyxBoard Member000 0000
Michael GreyAmplyxExecutive Chairman of the Board of Director000 0000
Niall O'Donnell Ph.DRiverVest Venture PartnersManaging Director000 0000
Paul Grint MDSelfBoard Member000 0000
Edward Mathers Partner New Enterprise Associates
Elaine Heron Ph.D Board Member Amplyx
Michael Grey Executive Chairman of the Board of Director Amplyx
Niall O'Donnell Ph.D Managing Director RiverVest Venture Partners
Paul Grint MD Board Member Self
Request full access to PitchBook